COVID-19 Neutralizing Antibody Surveillance Testing for Fully Vaccinated Individuals During Delta Variant Spread
This article has been Reviewed by the following groups
Discuss this preprint
Start a discussion What are Sciety discussions?Listed in
- Evaluated articles (ScreenIT)
Abstract
We recently performed 568 rapid neutralizing antibody (NAb) tests on 164 fully vaccinated individuals who received either Moderna or Pfizer COVID-19 vaccine regimens over 7 weeks. The NAb levels against the wild type (WA1/2020), Delta, and Kappa variants were measured and compared. Depending on each individual’s medical condition and vaccination status, the NAb levels for most of the fully vaccinated people decreased within 2-6 months, while a small number of individuals either generated non-detectable amount of NAbs after full vaccination (e.g., immunocompromised), or had high NAb levels lasting beyond 6 months. Since the NAb levels vary significantly among different individuals and decrease over time, the deployment of a low-cost rapid test to monitor NAb levels against both the wild type and emerging variants among fully vaccinated individuals can play a very crucial role to control the current pandemic. Our study provides an example of using such a rapid NAb test to fill this currently unmet medical need.
Article activity feed
-
SciScore for 10.1101/2021.10.01.21264371: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics not detected. Sex as a biological variable not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Table 2: Resources
Antibodies Sentences Resources The test is designed to detect neutralizing antibodies capable of blocking the binding between human Angiotensin-Converting Enzyme 2 (ACE2) and the SARS-CoV-2 virus spike Receptor Binding Domain (RBD) protein using a fingerstick blood sample. ACE2suggested: NoneFor this study, a competitive lateral flow immunoassay with a recombinant human ACE2 protein as a detector and an anti-RBD monoclonal antibody as a capture was used. anti-RBDsuggested: NoneResults from OddPub: We did not detect open data. We also did not detect …
SciScore for 10.1101/2021.10.01.21264371: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics not detected. Sex as a biological variable not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Table 2: Resources
Antibodies Sentences Resources The test is designed to detect neutralizing antibodies capable of blocking the binding between human Angiotensin-Converting Enzyme 2 (ACE2) and the SARS-CoV-2 virus spike Receptor Binding Domain (RBD) protein using a fingerstick blood sample. ACE2suggested: NoneFor this study, a competitive lateral flow immunoassay with a recombinant human ACE2 protein as a detector and an anti-RBD monoclonal antibody as a capture was used. anti-RBDsuggested: NoneResults from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
-
